Search Site
  • 0
    My Cart

    Click Here to Find How Many Items You Have Added:)

Home >> Signaling Pathways >> Tyrosine Kinase

Tyrosine Kinase

  1. Cat.No. Product Name Information
  2. GC68463 ULK1-IN-2 ULK1-IN-2 Chemical Structure
  3. GC68458 HS-243 HS-243 Chemical Structure
  4. GC68447 GSK143 dihydrochloride GSK143 dihydrochloride Chemical Structure
  5. GC68440 EGFR-IN-69 EGFR-IN-69 Chemical Structure
  6. GC68433 OTS447 OTS447 Chemical Structure
  7. GC68430 Selatinib Selatinib Chemical Structure
  8. GC68411 RORγt Inverse agonist 10 RORγt Inverse agonist 10 Chemical Structure
  9. GC68396 Vepafestinib Vepafestinib Chemical Structure
  10. GC68342 Tilvestamab Tilvestamab Chemical Structure
  11. GC68321 O-Desmethyl gefitinib-d8 O-Desmethyl gefitinib-d8 Chemical Structure
  12. GC68304 Margetuximab Margetuximab Chemical Structure
  13. GC68030 FAK-IN-7 FAK-IN-7 Chemical Structure
  14. GC68018 MET kinase-IN-2 MET kinase-IN-2 Chemical Structure
  15. GC67998 Insulin degludec Insulin degludec Chemical Structure
  16. GC67948 Cabozantinib-d6 Cabozantinib-d6 Chemical Structure
  17. GC67917 RET-IN-7 RET-IN-7 Chemical Structure
  18. GC67879 Edecesertib Edecesertib Chemical Structure
  19. GC67878 TL4830031 TL4830031 Chemical Structure
  20. GC67860 JBJ-09-063 TFA JBJ-09-063 TFA Chemical Structure
  21. GC67774 CT52923 CT52923 Chemical Structure
  22. GC67759 Lapatinib-d4 Lapatinib-d4 Chemical Structure
  23. GC67749 Amivantamab Amivantamab Chemical Structure
  24. GC67690 JBJ-09-063 hydrochloride JBJ-09-063 hydrochloride Chemical Structure
  25. GC52516 Erbstatin A tyrosine kinase inhibitor Erbstatin Chemical Structure
  26. GC52472 Inostamycin A (sodium salt) A bacterial metabolite with anticancer activity Inostamycin A (sodium salt) Chemical Structure
  27. GC66476 DDR1-IN-6 DDR1-IN-6 is a selective Discoidin Domain Receptor family, member 1 (DDR1) inhibitor with an IC50 of 9.72 nM. DDR1-IN-6 inhibits auto-phosphorylation DDR1b (Y513) with an IC50 of 9.7 nM. DDR1-IN-6 has anti-cancer activity. DDR1-IN-6 Chemical Structure
  28. GC66451 AKN-028 acetate AKN-028 acetate, a novel tyrosine kinase (TK) inhibitor, is a potent, orally active FMS-like receptor tyrosine kinase 3 (FLT3) inhibitor with an IC50 value of 6nM. AKN-028 acetate inhibits FLT3 autophosphorylation. AKN-028 acetate induces dose-dependent cytotoxic response (mean IC50=1μM). AKN-028 acetate induces apoptosisby activation of caspase 3. AKN-028 acetate can be used in research of acute myeloid leukemia (AML). AKN-028 acetate Chemical Structure
  29. GC66432 EAI001 EAI001 is a potent, selective mutant epidermal growth factor receptor (EGFR) allosteric inhibitor with an IC50 value of 24 nM for EGFRL858R/T790M. EAI001 can be used for research of cancer. EAI001 Chemical Structure
  30. GC66428 EGFR-IN-5 EGFR-IN-5 is a EGFR inhibitor with IC50s of 10.4, 1.1, 34, 7.2 nM for EGFR, EGFRL858R, EGFRL858R/T790M, and EGFRL858R/T790M/C797S, respectively. EGFR-IN-5 Chemical Structure
  31. GC66405 Panitumumab Panitumumab (ABX-EGF) is a fully human IgG2 anti-EGFR monoclonal antibody with anti-tumor activity. Panitumumab inhibits tumor cell proliferation, survival and angiogenesis. Panitumumab can be used in the research of cancers, such as colon cancer. Panitumumab Chemical Structure
  32. GC66385 Tovetumab Tovetumab (MEDI-575) is an anti-PDGFRα monoclonal antibody that selectively blocks the PDGFRα signal transduction. Tovetumab can be used in the research of glioblastoma and non-small cell lung cancer (NSCLC). Tovetumab Chemical Structure
  33. GC66349 Mavrilimumab Mavrilimumab (CAM 3001) is a monoclonal antibody that binds to the α subunit of the granulocyte-macrophage colony stimulating factor (GM-CSF) receptor and blocks intracellular signalling downstream of GM-CSF. GM-CSF might be a mediator of the hyperactive inflammatory response associated with respiratory failure and death. Mavrilimumab Chemical Structure
  34. GC66333 Panitumumab (anti-EGFR) Panitumumab (anti-EGFR) is a fully human IgG2 anti-EGFR monoclonal antibody with anti-tumor activity. Panitumumab (anti-EGFR) inhibits tumor cell proliferation, survival and angiogenesis. Panitumumab (anti-EGFR) can be used in the research of cancers, such as colon cancer. Panitumumab (anti-EGFR) Chemical Structure
  35. GC66327 Zilovertamab Zilovertamab (UC-961) is a humanised monoclonal antibody against ROR1 that blocks Wnt5a-induced ROR1 signalling. Zilovertamab Chemical Structure
  36. GC66043 VEGFR-2-IN-29 VEGFR-2-IN-29 (Compound 5) is a VEGFR-2 inhibitor with an IC50 of 16.5 nM. VEGFR-2-IN-29 Chemical Structure
  37. GC66028 c-Fms-IN-13 c-Fms-IN-13 (compound 14) is a potent FMS kinase inhibitor with an IC50 value of 17 nM. c-Fms-IN-13 can be used as an anti-inflammatory agent. c-Fms-IN-13 Chemical Structure
  38. GC65992 FGFR2-IN-3 FGFR2-IN-3 is an orally active selective inhibitor of FGFR2. FGFR2-IN-3 Chemical Structure
  39. GC65991 FGFR2-IN-3 hydrochloride FGFR2-IN-3 hydrochloride is an orally active selective inhibitor of FGFR2. FGFR2-IN-3 hydrochloride Chemical Structure
  40. GC65984 FLT3-IN-16 FLT3-IN-16 is a potent FLT3 inhibitor with an IC50 of 1.1 μM. FLT3-IN-16 can be used for researching acute myeloid leukemia. FLT3-IN-16 Chemical Structure
  41. GC65976 cFMS Receptor Inhibitor IV cFMS Receptor Inhibitor IV (Compound 42) is a potent cFMS inhibitor with an IC50 of 0.017 μM. cFMS Receptor Inhibitor IV Chemical Structure
  42. GC65974 EGFR-IN-9 EGFR-IN-9 (Compound 8) is a potent EGFR kinase inhibitor with IC50s of 7 nM, 28 nM for the wild type EGFR kinase and double mutant EGFR kinase (L858R/T790M). EGFR-IN-9 has antitumor activity. EGFR-IN-9 Chemical Structure
  43. GC65966 BPI-9016M BPI-9016M is a potent, orally active, and selective dual c-Met and AXL tyrosine kinases inhibitor. BPI-9016M suppresses tumor cell growth, migration and invasion of lung adenocarcinoma. BPI-9016M Chemical Structure
  44. GC65953 RORγt inverse agonist 23 RORγt inverse agonist 23 is a potent, selective, and orally available novel retinoic acid receptor-related orphan receptor γt inverse agonist. RORγt inverse agonist 23 Chemical Structure
  45. GC65948 c-Kit-IN-5-1 c-Kit-IN-5 is potent inhibitor of c-Kit, with IC50s of 22 nM and 16 nM in kinase assay and cell assay, respectively. c-Kit-IN-5 shows more than 200-fold selectivity for c-Kit over KDR, p38, Lck, and Src. c-Kit-IN-5 also exhibits desirable pharmacokinetic properties. c-Kit-IN-5-1 Chemical Structure
  46. GC65941 HS-276 HS-276 is an orally active, potent and highly selective TAK1 inhibitor, with a Ki of 2.5 nM. HS-276 shows significant inhibition of TAK1, CLK2, GCK, ULK2, MAP4K5, IRAK1, NUAK, CSNK1G2, CAMKKβ-1, and MLK1, with IC50 values of 8.25, 29, 33, 63, 125, 264, 270, 810, 1280, and 5585 nM, respectively. HS-276 can be used for rheumatoid arthritis (RA) research. HS-276 Chemical Structure
  47. GC65894 ABN401 ABN401 is a highly potent and selective ATP-competitive c-MET inhibitor with an IC50 value of 10 nM. ABN401 has cytotoxic activity against MET-addicted cancer cells. ABN401 can inhibit c-MET phosphorylation in tumor tissues. ABN401 can be used for researching anticancer. ABN401 Chemical Structure
  48. GC65886 BI-853520 BI 853520 (IN-10018) is an orally active and potent focal adhesion kinase (FAK) inhibitor (recombinant FAK IC50=1nM). BI 853520 shows anti-proliferative activity against cancer cells. BI-853520 Chemical Structure
  49. GC65592 SNIPER(ABL)-020 SNIPER(ABL)-020, conjugating Dasatinib (ABL inhibitor) to Bestatin (IAP ligand) with a linker, induces the reduction of BCR-ABL protein. SNIPER(ABL)-020 Chemical Structure
  50. GC65572 EGFR Protein Tyrosine Kinase Substrate EGFR Protein Tyrosine Kinase Substrate is a EGFR protein tyrosine kinase substrate. EGFR Protein Tyrosine Kinase Substrate Chemical Structure
  51. GC65555 PROTAC FLT-3 degrader 1 PROTAC FLT-3 degrader 1 is a von Hippel-Lindau-based PROTAC FLT-3 internal tandem duplication (ITD) degrader with an IC50 0.6 nM. Anti-proliferative activity; apoptosis induction. PROTAC FLT-3 degrader 1 Chemical Structure
  52. GC65516 Bemarituzumab Bemarituzumab is a first-in-class, humanized IgG1 monoclonal antibody against FGFR2b (a FGF receptor). Bemarituzumab blocks fibroblast growth factors from binding and activating FGFR2b. Bemarituzumab has the potential for cancer research. Bemarituzumab Chemical Structure
  53. GC65515 Aprutumab Aprutumab?(BAY 1179470) is a fully human FGFR2 monoclonal antibody, which binds to the FGFR2 isoforms FGFR2-IIIb and FGFR2-IIIc. Aprutumab has?the?potential?for?solid tumors research. Aprutumab Chemical Structure
  54. GC65478 Gemnelatinib Gemnelatinib is a tyrosine kinase inhibitor (WO2018077227, implementation example 1). Gemnelatinib can be used for the research of cancer. Gemnelatinib Chemical Structure
  55. GC65457 BI-3663 BI-3663 is a highly selective PTK2/FAK PROTAC (DC50=30 nM), with Cereblon ligands to hijack E3 ligases for PTK2 degradation. BI-3663 inhibits PTK2 with an IC50 of 18 nM. BI-3663 is a PROTAC that composes of BI-4464 linked to Pomalidomide with a linker. Anti-cancer activity. BI-3663 Chemical Structure
  56. GC65436 JND3229 JND3229 is a reversible EGFRC797S inhibitor with IC50 values of 5.8, 6.8 and 30.5 nM for EGFRL858R/T790M/C797S, EGFRWT and EGFRL858R/T790M, respectively. JND3229 has good anti-proliferative activity and can effectively inhibit tumour growth in vivo. JND3229 can be used in cancer research, especially in non-small cell carcinoma. JND3229 Chemical Structure
  57. GC65395 T025 T025 is an orally active and highly potent inhibitor of Cdc2-like kinase (CLKs), with Kd values of 4.8, 0.096, 6.5, 0.61, 0.074, 1.5 and 32 nM for CLK1, CLK2, CLK3, CLK4, DYRK1A, DYRK1B and DYRK2, respectively. T025 induces caspase-3/7-mediated cell apoptosis. T025 reduces CLK-dependent phosphorylation. T025 exerts anti-proliferative activities in both hematological and solid cancer cell lines (IC50 values: 30-300 nM). T025 has an anti-tumor efficiency, mainly for MYC-driven disease research. T025 Chemical Structure
  58. GC65390 LRRK2 inhibitor 1 LRRK2 inhibitor 1 is a potent, selective and oral LRRK2 inhibitor with an pIC50 of 6.8. LRRK2 inhibitor 1 Chemical Structure
  59. GC65380 Envonalkib Envonalkib is a potent and orally active inhibitor of ALK, with IC50s of 1.96 nM, 35.1 nM, and 61.3 nM for WT and mutated L1196M and G1269S-ALK. Envonalkib can be used for the research of non-small cell lung cancer. Envonalkib Chemical Structure
  60. GC65378 DDR1-IN-5 DDR1-IN-5 is a selective Discoidin Domain Receptor family, member 1 (DDR1) inhibitor with an IC50 of 7.36 nM. DDR1-IN-5 inhibits auto-phosphorylation DDR1b (Y513) with an IC50 of 4.1 nM. DDR1-IN-5 has anti-cancer activity. DDR1-IN-5 Chemical Structure
  61. GC65366 PDGFRα kinase inhibitor 1 PDGFRα kinase inhibitor 1 is a highly selective type II PDGFRα kinase inhibitor with IC50s of 132 nM and 6115 nM for PDGFRα and PDGFRβ, respectively. PDGFRα kinase inhibitor 1 Chemical Structure
  62. GC65354 Enbezotinib Enbezotinib, an inhibitor of RET, can inhibit the RET autophosphorylation. Enbezotinib can be used for the research of cancer. Enbezotinib Chemical Structure
  63. GC65335 PTC299 PTC299 is an orally active inhibitor of VEGFA mRNA translation that selectively inhibits VEGF protein synthesis at the post-transcriptional level. PTC299 is also a potent inhibitor of dihydroorotate dehydrogenase (DHODH). PTC299 shows good oral bioavailability and lack of off-target kinase inhibition and myelosuppression. PTC299 can be useful for the research of hematologic malignancies. PTC299 Chemical Structure
  64. GC65310 TAS0728 TAS0728 is a potent, selective, orally active, irreversible and covalent-binding HER2 inhibitor, with an IC50 of 13 nM. TAS0728 also shows IC50s of 4.9, 8.5, 31, 65, 33, 25 and 86 nM for BMX、HER4、BLK、EGFR、JAK3、SLK and LOK respectively. Furthermore, TAS0728 exhibits robust and sustained inhibition of the phosphorylation of HER2 TAS0728 Chemical Structure
  65. GC65243 MS4077 MS4077 is an anaplastic lymphoma kinase (ALK) PROTAC (degrader) based on Cereblon ligand, with a Kd of 37?nM for binding affinity to ALK. MS4077 Chemical Structure
  66. GC65212 FGFR1/DDR2 inhibitor 1 FGFR1/DDR2 inhibitor 1 is an orally active inhibitor of fibroblast growth factor receptor 1 (FGFR1) and discoindin domain receptor 2 (DDR2), with IC50 values of 31.1 nM and 3.2 nM, respectively. Antitumor activity. FGFR1/DDR2 inhibitor 1 Chemical Structure
  67. GC65179 MAX-40279 MAX-40279 is a dual and potent inhibitor of FLT3 kinase and FGFR kinase. MAX-40279 Chemical Structure
  68. GC65155 S18-000003 S18-000003 is a potent, selective and orally active inhibitor of retinoic acid receptor-related orphan receptor-gamma-t (RORγt), with an IC50 of <30 nM towards human RORγt in competitive binding assays. S18-000003 Chemical Structure
  69. GC65134 HIV-IN-6 HIV-IN-6 is a HIV-Ⅰ viral replication inhibitor by targeting Src family kinases (SFK) that interact with Nef protein of the virus, such as Hck. HIV-IN-6 Chemical Structure
  70. GC65009 PF-6683324 PF-6683324 (Trk-IN-4) is a potent pan-Trk inhibitor in cell-based assays withIC50s of 1.9 nM, 2.6 nM and 1.1 nM for TrkA, TrkB and TrkC, respectively. PF-6683324 Chemical Structure
  71. GC64996 Tivozanib hydrochloride hydrate Tivozanib hydrochloride hydrate is a potent and selective and orally active VEGFR tyrosine kinase inhibitor with IC50是of 0.21, 0.16, 0.24 nM for VEGFR-1, VEGFR-2, VEGFR-3, respectively. Tivozanib hydrochloride hydrate inhibits angiogenesis and vascular permeability in tumor tissues and shows antitumor activity. Tivozanib hydrochloride hydrate has the potential for the research of metastatic renal cell carcinoma (RCC) . Tivozanib hydrochloride hydrate Chemical Structure
  72. GC64992 YH-306 YH-306 is an antitumor agent. YH-306 suppresses colorectal tumour growth and metastasis via FAK pathway. YH-306 significantly inhibits the migration and invasion of colorectal cancer cells. YH-306 potently suppresses uninhibited proliferation and induces cell apoptosis. YH-306 suppresses the activation of FAK, c-Src, paxillin, and PI3K, Rac1 and the expression of MMP2 and MMP9. YH-306 also inhibita actin-related protein (Arp2/3) complex-mediated actin polymerization. YH-306 Chemical Structure
  73. GC64966 MS4078 MS4078 is an anaplastic lymphoma kinase (ALK) PROTAC (degrader) based on Cereblon ligand, with a Kd of 19?nM for binding affinity to ALK. MS4078 Chemical Structure
  74. GC64961 CSF1R-IN-2 CSF1R-IN-2 (compound 5) is an oral-active inhibitor of SRC, MET and c-FMS, with IC50 values of 0.12 nM, 0.14 nM and 0.76 nM for SRC, MET and c-FMS respectively. CSF1R-IN-2 Chemical Structure
  75. GC64950 ODM-203 ODM-203 is an orally active and selective FGFR/VEGFR inhibitor with IC50 values of 6, 11, 16, 5, 9, 26 and 35 nM for FGFR3/1/2 and VEGFR3/2/1/4, respectively. ODM-203 has strong anti-tumour activity and activates immune responses in the tumour microenvironment. ODM-203 Chemical Structure
  76. GC64947 Glumetinib Glumetinib (SCC244) is a highly selective, orally bioavailable, ATP-competitive c-Met inhibitor with an IC50 of 0.42 nM. Glumetinib has greater than 2400-fold selectivity for c-Met over those 312 kinases evaluated, including the c-Met family member RON and highly homologous kinases Axl, Mer, TyrO3. Antitumor activity. Glumetinib Chemical Structure
  77. GC64895 Regorafenib-d3 Regorafenib D3 (BAY 73-4506 D3) is a deuterium labeled Regorafenib. Regorafenib is a multi-targeted receptor tyrosine kinase inhibitor. Regorafenib-d3 Chemical Structure
  78. GC64889 GSK2646264 GSK2646264 (Compound 44) is a potent and selective spleen tyrosine kinase (SYK) inhibitor with a pIC50 of 7.1. GSK2646264 Chemical Structure
  79. GC64888 GSK215 GSK215 is a potent and selective PROTAC focal adhesion kinase (FAK) degrader with a pDC50 of 8.4. GSK215 is designed by a binder for the VHL E3 ligase and the FAK inhibitor VS-4718. GSK215 induces rapid and prolonged FAK degradation, giving a long-lasting effect on FAK levels and a marked pharmacokinetic/pharmacodynamics (PK/PD) disconnect. GSK215 Chemical Structure
  80. GC64875 Gunagratinib Gunagratinib (ICP-192) is a low toxicity and orally active pan-FGFR (fibroblast growth factor receptors) inhibitor that potently and selectively inhibits FGFR activities irreversibly by covalent binding. Gunagratinib can be used for the research of cancer. Gunagratinib Chemical Structure
  81. GC64856 UniPR129 UniPR129 is a potent Eph/ephrin antagonist. UniPR129 has the potential for the research of cancer disease. UniPR129 Chemical Structure
  82. GC64836 Famitinib Famitinib (SHR1020), an orally active multi-targeted kinase inhibitor, inhibits the activity of c-kit, VEGFR-2 and PDGFRβ with IC50 values of 2.3 nM, 4.7 nM and 6.6 nM, respectively. Famitinib exerts powerful antitumor activity in human gastric cancer cells and xenografts. Famitinib triggers apoptosis. Famitinib Chemical Structure
  83. GC64810 Bezuclastinib Bezuclastinib (CGT9486; PLX 9486) is a potent inhibitor of c-kit and c-kit D816V (0.0001 Bezuclastinib Chemical Structure
  84. GC64805 CSF1R-IN-3 CSF1R-IN-3 (compound 21) is a potent and orally active CSF-1R inhibitor (IC50=2.1 nM). CSF1R-IN-3 is a potent antiproliferative activity against colorectal cancer cells. CSF1R-IN-3 inhibits the progression of colorectal cancer by suppressing the migration of macrophages, reprograming M2-like macrophages to the M1 phenotype, and enhancing the antitumor immunity. CSF1R-IN-3 Chemical Structure
  85. GC64770 Oritinib Oritinib (SH-1028), an irreversible third-generation EGFR TKI, overcomes T790M-mediated resistance in non-small cell lung cancer. Oritinib (SH-1028), a mutant-selective inhibitor of EGFR kinase activity, inhibits EGFRWT, EGFRL858R, EGFRL861Q, EGFRL858R/T790M, EGFRd746-750 and EGFRd746-750/T790M kinases, with IC50s of 18, 0.7, 4, 0.1, 1.4 and 0.89 nM, respectively. Oritinib Chemical Structure
  86. GC64730 EB-42486 EB-42486 is a novel, potent, and highly selective G2019S-LRRK2 inhibitor (IC50 < 0.2 nM). EB-42486 Chemical Structure
  87. GC64725 GNF2133 hydrochloride GNF2133 hydrochloride is a potent, selective and orally active DYRK1A inhibitor with IC50s of 0.0062, >50 ?M for DYRK1A and GSK3β, respectively. GNF2133 hydrochloride Chemical Structure
  88. GC64724 GNF2133 GNF2133 is a potent, selective and orally active DYRK1A inhibitor with IC50s of 0.0062, >50 ?M for DYRK1A and GSK3β, respectively. GNF2133 Chemical Structure
  89. GC64710 MC-Val-Cit-PAB-Amide-TLR7 agonist 4 MC-Val-Cit-PAB-Amide-TLR7 agonist 4 (example 15) is a HER2-TLR7 and HER2-TLR8 immune agonist conjugate. MC-Val-Cit-PAB-Amide-TLR7 agonist 4 Chemical Structure
  90. GC64708 Fosgonimeton Fosgonimeton (ATH-1017) is a hepatocyte growth factor receptor agonist (WO2017210489). Fosgonimeton Chemical Structure
  91. GC64683 AVJ16 AVJ16 is a member of the insulin-like growth factor 2 mRNA-binding protein family. AVJ16 regulates protein translation by binding to the mRNAs of certain genes. AVJ16 Chemical Structure
  92. GC64583 MAX-40279 hemiadipate MAX-40279 hemiadipate is a dual and potent inhibitor of FLT3 kinase and FGFR kinase. MAX-40279 hemiadipate Chemical Structure
  93. GC64582 MAX-40279 hemifumarate MAX-40279 hemifumarate is a dual and potent inhibitor of FLT3 kinase and FGFR kinase. MAX-40279 hemifumarate Chemical Structure
  94. GC64566 PF-06454589 PF-06447475 is a highly potent, selective, brain penetrant LRRK2 kinase inhibitor with IC50 values of 3 nM and 11 nM for WT LRRK and G2019S LRRK2, respectively. PF-06454589 Chemical Structure
  95. GC64564 Caffeic acid-pYEEIE TFA Caffeic acid-pYEEIE TFA, a non-phosphopeptide inhibitor, exhibits potent binding affinity for the GST-Lck-SH2 domain. Caffeic acid-pYEEIE TFA Chemical Structure
  96. GC64506 PF-06456384 trihydrochloride PF-06447475 trihydrochloride is a highly potent, selective, brain penetrant LRRK2 kinase inhibitor with IC50 values of 3 nM and 11 nM for WT LRRK and G2019S LRRK2, respectively. PF-06456384 trihydrochloride Chemical Structure
  97. GC64497 EGFR-IN-17 EGFR-IN-17 is a potent and selective inhibitor of the epidermal growth factor receptor ( IC50 0.0002 μM) to overcome C797S-mediated resistance. EGFR-IN-17 Chemical Structure
  98. GC64475 FGFR2-IN-2 FGFR2-IN-2 (Compound 38) is a selective FGFR2 inhibitor with IC50s of 389, 29, and 758 nM for FGFR1, FGFR2, and FGFR3, respectively. FGFR2-IN-2 Chemical Structure
  99. GC64462 Asciminib hydrochloride Asciminib (ABL001) hydrochloride is a potent and selective allosteric BCR-ABL1 inhibitor, which inhibits Ba/F3 cells grown with an IC50 of 0.25 nM. Asciminib hydrochloride Chemical Structure
  100. GC64431 MSDC-0602K MSDC-0602K (Azemiglitazone potassium), a PPARγ-sparing thiazolidinedione (Ps-TZD), binds to PPARγ with the IC50 of 18.25 μM. MSDC-0602K Chemical Structure
  101. GC64398 Almonertinib mesylate Almonertinib (HS-10296) mesylate is an orally available, irreversible, third-generation EGFR tyrosine kinase inhibitor with high selectivity for EGFR-sensitizing and T790M resistance mutations. Almonertinib mesylate shows great inhibitory activity against T790M, T790M/L858R and T790M/Del19 (IC50: 0.37, 0.29 and 0.21 nM, respectively), and is less effective against wild type (3.39 nM). Almonertinib mesylate is used for the research of the non-small cell lung cancer. Almonertinib mesylate Chemical Structure

Items 1 to 100 of 1071 total

per page
  1. 1
  2. 2
  3. 3
  4. 4
  5. 5

Set Descending Direction